Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials.

Abstract:

BACKGROUND:Ewing tumors are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. Optimal local control remains controversial. The aim of this study was to analyze treatment, outcome, and surgical procedures in patients with thoracic tumors of the Ewing sarcoma family (TES) treated within four Cooperative Soft-Tissue Sarcoma (CWS) trials and one registry. PATIENTS AND METHODS:Sixty-two patients from 0 to 21 years treated between 1981 and 2014 were selected for this analysis. A retrospective chart analysis was carried out. Institutional review board approval was obtained for all trials. RESULTS:The median age of the patients was 7 years. The 5-year overall (OS) and event-free survival (EFS) rates were 58.7% (52.7-64.7) and 52.8% (46.8-58.8). Patients with intrathoracic tumor localization (n = 24) had a worse outcome (EFS: 37.5%; 27.5-37.5) compared with those with chest wall tumors (n = 38; EFS: 62.3%; 54.3-70.3, P = 0.008). Patients ≤10 years (n = 38) had a better survival compared with those > 10 years (EFS: 65.7%; 57.7-73.7 vs 31.3%; 21.3-41.3, P = 0.01). Tumor size ≤5 cm (n = 15) was associated with significantly better survival compared with a size > 5 cm (n = 47, EFS: 93.3%; 87.3-99.3 vs 40%; 33-47, P = 0.002). Primary resections were carried out in 36 patients, of which 75% were incomplete resulting in inferior EFS (P = 0.006). Complete secondary resections were performed in 22 of 40. CONCLUSIONS:Positive predictive factors for outcome are age ≤10 years, size ≤5 cm, and localization at the chest wall. Diverse IRS groups require individual treatment.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Seitz G,Urla C,Sparber-Sauer M,Schuck A,Vokuhl C,Blank B,Klingebiel T,Kazanowska B,Fuchs J,Koscielniak E

doi

10.1002/pbc.27884

subject

Has Abstract

pub_date

2019-08-01 00:00:00

pages

e27884

eissn

1545-5009

issn

1545-5017

journal_volume

66 Suppl 3

pub_type

更正并重新发布的文章,杂志文章
  • Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting.

    abstract::Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal stem cell disorder. Eculizumab and bone marrow transplantation are disease-modifying treatments for PNH but may not be readily available in resource-constrained settings. Of 52 pediatric patients with PNH, 20 had classical PNH and 32 had PNH/aplastic ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27712

    authors: Halder R,Mishra P,Aggarwal M,Mannivanan P,Dhawan R,Seth T,Tyagi S,Mahapatra M,Pati HP,Saxena R

    更新日期:2020-04-01 00:00:00

  • Intensity-modulated radiation therapy with dose-painting for pediatric sarcomas with pulmonary metastases.

    abstract:BACKGROUND:We examined patterns of failure in pediatric patients with thoracic sarcoma and pulmonary metastases treated with intensity-modulated radiation therapy with dose-painting (DP-IMRT). PROCEDURE:Eleven pediatric patients, five with Ewing sarcoma family tumors (ESFT) and six with rhabdomyosarcoma (RMS), with pr...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.24502

    authors: Yang JC,Wexler LH,Meyers PA,Happersett L,La Quaglia MP,Wolden SL

    更新日期:2013-10-01 00:00:00

  • Treatment of infantile choriocarcinoma of the liver.

    abstract::Primary choriocarcinoma of the liver is an extremely rare childhood malignancy frequently associated with clinical instability at initial presentation. It often mimics other benign and malignant childhood liver tumors. Prompt diagnosis and initiation of treatment are necessary to attain a successful outcome. We descri...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20623

    authors: Yoon JM,Burns RC,Malogolowkin MH,Mascarenhas L

    更新日期:2007-07-01 00:00:00

  • Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong.

    abstract:BACKGROUND AND AIM:We reviewed the results and pattern of failure of the consensus HB/HCC 1996 treatment protocol for pediatric hepatoblastoma (HB) in Hong Kong. The role of SIOPEL and Children's Hepatic tumors International Collaboration (CHIC) risk stratification was evaluated. METHODS:Patients enrolled on the proto...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27482

    authors: Liu APY,Ip JJK,Leung AWK,Luk CW,Li CH,Ho KKH,Lo R,Chan EKW,Chan ACY,Chung PHY,Chiang AKS

    更新日期:2019-01-01 00:00:00

  • New targets for antibody therapy of pediatric B cell lymphomas.

    abstract::Antibody therapy has become standard of care for adult B cell lymphoma patients. It is a potentially less toxic and more targeted approach for lymphoma therapy and should therefore be applied to treat pediatric B cell lymphoma patients as well. In pediatric lymphoma patients, however, clinical experience with monoclon...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.25193

    authors: van Vuren A,Meyer-Wentrup F

    更新日期:2014-12-01 00:00:00

  • Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

    abstract:BACKGROUND:For children with juvenile myelomonocytic leukemia (JMML) who undergo stem cell transplantation (SCT), the role of immunological interventions including withdrawal of immunosuppressive therapy (IST) and donor lymphocyte infusion (DLI) for treatment of disease recurrence remains uncertain. PROCEDURE:We analy...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24259

    authors: Inagaki J,Fukano R,Nishikawa T,Nakashima K,Sawa D,Ito N,Okamura J

    更新日期:2013-01-01 00:00:00

  • Chickenpox in varicella IgG positive patients: experience of a regional paediatric oncology centre.

    abstract::Aciclovir prophylaxis was previously given to all immunocompromised patients treated by our unit, following contact with varicella zoster. In 2003, we changed practice according to National Guidelines, giving prophylaxis only to patients without serum varicella zoster immunoglobulin G antibody (VZ IgG) at diagnosis of...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21521

    authors: Manley S,Mallinson H,Caswell M,Keenan R,Pizer B

    更新日期:2008-10-01 00:00:00

  • Familial retinoblastoma in developing countries.

    abstract:BACKGROUND:Although screening for familial retinoblastoma has been shown to be beneficial we suspected that such screening programs may be less than optimal in developing countries (DC). METHODS:Retrospective cohort study comparing patients with familial retinoblastoma from five centers in DC (Argentina, Brazil, Turke...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21970

    authors: Chantada GL,Dunkel IJ,Qaddoumi I,Antoneli CB,Totah A,Canturk S,Nawaiseh I,Fandiño A,Pífano I,Peksayar G,Ribeiro KB,Abramson DH

    更新日期:2009-09-01 00:00:00

  • Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors.

    abstract:BACKGROUND:Childhood germ cell tumors (cGCTs), believed to arise from transformed primordial germ cells by an unknown mechanism, provide a unique model system for investigating cell signaling, pluripotency, and the microenvironment of neoplastic stem cells (NSCs) in vivo. This is the first report of proteomics of cGCTs...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23282

    authors: Haskins WE,Eedala S,Jadhav YL,Labhan MS,Pericherla VC,Perlman EJ

    更新日期:2012-05-01 00:00:00

  • Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee.

    abstract::The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standardized regimen of imaging examinations performed prior to, during, and fo...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,实务指引

    doi:10.1002/pbc.21596

    authors: Meyer JS,Nadel HR,Marina N,Womer RB,Brown KL,Eary JF,Gorlick R,Grier HE,Randall RL,Lawlor ER,Lessnick SL,Schomberg PJ,Kailo MD

    更新日期:2008-08-01 00:00:00

  • Treatment of the X-linked lymphoproliferative, Griscelli and Chédiak-Higashi syndromes by HLH directed therapy.

    abstract:BACKGROUND:Griscelli syndrome type 2 (GS2), the X-linked lymphoproliferative (XLP) and the Chédiak-Higashi (CHS) syndromes are diseases that all may develop hemophagocytic syndromes. We wanted to investigate whether the treatment protocols for hemophagocytic lymphohistiocytosis (HLH) can also be used for these syndrome...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21790

    authors: Trottestam H,Beutel K,Meeths M,Carlsen N,Heilmann C,Pasić S,Webb D,Hasle H,Henter JI

    更新日期:2009-02-01 00:00:00

  • Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.

    abstract:BACKGROUND:Irinotecan is highly active against rhabdomyosarcoma (RMS), yet its tolerability and efficacy in combination with radiation is unknown. We examined local control and toxicities in RMS patients treated with radiotherapy (RT) in combination with radiosensitizing agents irinotecan + carboplatin (I + C). PROCED...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24205

    authors: Dharmarajan KV,Wexler LH,Wolden SL

    更新日期:2013-02-01 00:00:00

  • Minimally disseminated disease and outcome in overt orbital retinoblastoma.

    abstract::In this retrospective study of patients with overt orbital retinoblastoma, we evaluated minimally disseminated disease (MDD) in bone marrow and cerebrospinal fluid (CSF) using CRX and/or GD2 synthase as markers. Ten patients were evaluated-five (50%) at diagnosis and five upon relapse. MDD was detected in four cases (...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27662

    authors: Aschero R,Torbidoni A,Sampor C,Laurent V,Zugbi S,Winter U,Lubieniecki F,Alonso D,Schaiquevich P,Chantada GL

    更新日期:2019-06-01 00:00:00

  • Osteoporosis in children with cancer.

    abstract::As increasing numbers of childhood cancer patients are surviving, the long-term complications of the disease and its treatment have become ever more increasingly important. Reduced bone mineral density and increased fracture risk have been reported during and after treatment of children with cancer. The causes of oste...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.21407

    authors: van der Sluis IM,van den Heuvel-Eibrink MM

    更新日期:2008-02-01 00:00:00

  • Determinants of quality of life outcomes for survivors of pediatric brain tumors.

    abstract:INTRODUCTION:To describe the quality of life (QOL) of pediatric brain tumor survivors (PBTSs) prospectively and to identify potential medical, personal and family contextual factors associated with QOL. METHODS:Ninety-one PBTSs (8-16 years) who were off treatment and attending a regular classroom participated. Self- a...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26481

    authors: Barrera M,Atenafu EG,Schulte F,Bartels U,Sung L,Janzen L,Chung J,Cataudella D,Hancock K,Saleh A,Strother D,McConnell D,Downie A,Hukin J,Zelcer S

    更新日期:2017-09-01 00:00:00

  • Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.

    abstract::Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. The hypomethylating agent, azacitidine, has been used as a bridging therapy to transplant. However, no patients have been treated with azacitidine without an ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27905

    authors: Hashmi SK,Punia JN,Marcogliese AN,Gaikwad AS,Fisher KE,Roy A,Rao P,Lopez-Terrada DH,Ringrose J,Loh ML,Niemeyer CM,Rau RE

    更新日期:2019-10-01 00:00:00

  • Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

    abstract:BACKGROUND:Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival. PROCEDURES:Alvespimycin was tested against the in vitro panel of the Pediat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21508

    authors: Smith MA,Morton CL,Phelps DA,Kolb EA,Lock R,Carol H,Reynolds CP,Maris JM,Keir ST,Wu J,Houghton PJ

    更新日期:2008-07-01 00:00:00

  • Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.

    abstract:BACKGROUND:Cancer patients undergoing chemotherapy often develop anemia, which can increase the risk for transfusions and fatigue. The recombinant erythropoiesis-stimulating agent darbepoetin alfa can effectively treat chemotherapy-induced anemia (CIA) in adults, but limited data are available regarding its use in pedi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21079

    authors: Blumer J,Berg S,Adamson PC,Loew T,Rossi G,Hastings C

    更新日期:2007-10-15 00:00:00

  • Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

    abstract:BACKGROUND:M6620 is a novel inhibitor of the DNA damage repair enzyme ATR, and has potentiated the activity of cisplatin and irinotecan in non-small cell lung cancer and colon cancer xenografts, respectively. PROCEDURES:M6620 was tested in vitro at concentrations ranging from 1.0 nM to 10.0 μM and at 75 nM in combinat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26825

    authors: Kurmasheva RT,Kurmashev D,Reynolds CP,Kang M,Wu J,Houghton PJ,Smith MA

    更新日期:2018-02-01 00:00:00

  • Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature.

    abstract:BACKGROUND:Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is rarely observed. PROCEDURE:We treated a 14-year-old female who had multiple osteolytic lesions and hypercalcemia at initial onset of ALL. ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.20357

    authors: Shimonodan H,Nagayama J,Nagatoshi Y,Hatanaka M,Takada A,Iguchi H,Oda Y,Okamura J

    更新日期:2005-09-01 00:00:00

  • Addressing implicit bias in pediatric hematology-oncology.

    abstract::Although awareness of implicit bias and its influence on providers and patients is increasing, the effects of implicit bias on the field of pediatric hematology-oncology are less clear. This Special Report reviews the literature on implicit bias in pediatrics and medical oncology and further provides case examples and...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.28204

    authors: Tsai JW,Kesselheim JC

    更新日期:2020-05-01 00:00:00

  • Improving outcomes for high-risk ALL: translating new discoveries into clinical care.

    abstract::High-risk (HR) acute lymphoblastic leukemia (ALL) remains one of the greatest challenges in pediatric oncology. Relapsed ALL is a leading cause of death in young people, and further improvements in outcome will required the development of therapeutic approaches directed against rational therapeutic targets, as escalat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.22996

    authors: Hunger SP,Raetz EA,Loh ML,Mullighan CG

    更新日期:2011-06-01 00:00:00

  • Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.

    abstract:BACKGROUND:Treatment intensification was considered a suitable strategy to increase the cure rate of lymphoblastic lymphoma (LBL) in children. PROCEDURE:The AIEOP LNH-97 trial was run between 1997 and 2007 for newly diagnosed LBL in patients aged less than 18 years. Treatment schedule was based on the previous, LSA2-L...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.25469

    authors: Pillon M,Aricò M,Mussolin L,Carraro E,Conter V,Sala A,Buffardi S,Garaventa A,D'Angelo P,Lo Nigro L,Santoro N,Piglione M,Lombardi A,Porta F,Cesaro S,Moleti ML,Casale F,Mura R,d'Amore ES,Basso G,Rosolen A

    更新日期:2015-08-01 00:00:00

  • Prognostic impact of diagnostic and treatment delays in children with osteosarcoma.

    abstract:BACKGROUND:The aim of this study is to evaluate the relationship between the latency to diagnosis (LD) and the time to completion of chemotherapy (TCC) with clinical outcomes in children with osteosarcoma. METHODS:We performed a retrospective analysis of all patients who received treatment for osteosarcoma in two tert...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/pbc.28180

    authors: Vasquez L,Silva J,Chavez S,Zapata A,Diaz R,Tarrillo F,Maza I,Sialer L,García J

    更新日期:2020-04-01 00:00:00

  • A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

    abstract:BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24271

    authors: Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

    更新日期:2013-03-01 00:00:00

  • Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly.

    abstract:BACKGROUND:Pegasparaginase (PEG) is important for treatment of Acute Lymphoblastic Leukemia (ALL). Despite conjugation to polyethylene glycol to reduce immunogenicity, allergic reactions still occur and may be severe. Traditionally, PEG is given via intramuscular (IM) injection but recent protocols have shown it can be...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23380

    authors: Pidaparti M,Bostrom B

    更新日期:2012-09-01 00:00:00

  • Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.

    abstract:BACKGROUND:The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial. The purpose of this study was to demonstrate efficacy of a chemotherapy only strategy, with less morbidity, when compared to regimens with irradiation. METHODS:Between January 2001 and December 2004 newly diagnosed p...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.22381

    authors: da Silva NS,Cappellano AM,Diez B,Cavalheiro S,Gardner S,Wisoff J,Kellie S,Parker R,Garvin J,Finlay J

    更新日期:2010-03-01 00:00:00

  • Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years.

    abstract:BACKGROUND:In the pediatric population, pathologic bleeding is often challenging to identify. The pediatric bleeding questionnaire (PBQ) was developed as a screening tool for von Willebrand disease (VWD) but was designed to be self-completed by children above 12 years of age. The study objective was to determine whethe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27709

    authors: Bui J,Martyres D,James PD,Grabell J,Wu J,Steele M,Silva M,Rand ML,Blanchette VS,Barrowman N,Klaassen RJ

    更新日期:2019-06-01 00:00:00

  • The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols.

    abstract:BACKGROUND:Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy. PROCEDURES:Retrospectively, we estimated the effect of CNS involvement and...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26191

    authors: Taskinen M,Oskarsson T,Levinsen M,Bottai M,Hellebostad M,Jonsson OG,Lähteenmäki P,Schmiegelow K,Heyman M

    更新日期:2017-02-01 00:00:00

  • Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study.

    abstract::Progress has been made in resource-limited countries in treating acute lymphoblastic leukemia, but advances in solid malignancies have been slower. Multidisciplinary care coordination is challenging, assessing adherence to guidelines through quality improvement initiatives is essential. We characterized deviations fro...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26480

    authors: Power-Hays A,Friedrich P,Fernandez G,Cruz NA,Marcus K,Rodriguez-Galindo C,Collado L

    更新日期:2017-08-01 00:00:00